Moray Medical is working to improve the quality of life for the millions suffering with leaky heart valves. Using our proprietary microfluidic robotics, more cardiologists can safely and cost-effectively treat the large number of patients who need mitral valve clip therapies.
Extending the Benefits of Heart Repair
Heart mitral valve repair has not reached the masses. Open-heart surgery, the historical standard of care, is highly invasive and too risky for the vast majority who would benefit. Transcatheter mitral valve procedures, with access through the veins, are minimally invasive, but are difficult to perform. However, low trauma therapy works! The Transcatheter Edge-to-Edge Repair (TEER), or clip therapy, is rapidly becoming the new standard of care.
The 2018 COAPT trial shows that percutaneous interventions (with access through blood vessels) can be equally successful and is much less traumatic than open-heart surgery. Unfortunately, the complexity of the current mechanical instrumentation requires a long learning curve that prohibits mass adoption. A consequence only 2% of sufferers are treated and there are millions of new patients each year.
Moray Medical is simplifying the percutaneous delivery of valve therapies for interventional cardiologists of all skill levels. Millions of patients will benefit from this cost-effective and easy-to-learn-and-use delivery system. A larger and more dispersed group of interventionalists will be able to successfully treat patients with leaking heart valves.
Today, when placing a valve clip, the delivery system is not intuitive. The mitral valve edge-to-edge procedure typically requires four hands and two highly skilled interventional doctors. Even the most elite teams are challenged. Implanting clips is time-consuming, expensive, and is generally performed in a few specialized urban centers.
Moray’s robotic system, with its digital user interface, enables a single hand to control the placement of a clip. Powered by microfluidics, the catheter system is fast, precise, and intuitive; yet comparable in size to existing manual systems, and costs less to manufacture.
The structural heart market is one of the fastest growing medical-device fields. The market’s growth has accelerated with the rise of the Transcatheter Mitral Valve repair (TMVr) treatments, and more specifically Transcatheter Edge-to-Edge Repair (TEER), which is already a multibillion-dollar market. Mitral regurgitation (MR), or leakage of the heart’s mitral valve, affects millions of people, but only a small percentage are treated. As technologies advance and accessibility to treatment goes up, the demand for mitral valve repairs will greatly increase.
Moray Medical’s initial product is the Coral™ System, which includes a reusable Driver Assembly, a single-use Clipper™ toolset, and a Trident™ input device. The Clipper™ toolset includes a cardiac-valve-therapy edge-to-edge clip implant that is pre-mounted on a single-use fluid-driven steerable delivery catheter. The Driver, a wireless capital-equipment unit about the size of a brick, incorporates software to direct movement of the steerable Clipper™ toolset in response to input from a user. With robotic coordination, augmented reality (AR) visualization, and Moray’s Submersion™ interface, the interventionist can position and orient the clip as easily as moving a cursor on a screen.
Two MedTech professionals, an attorney and a scientist, with roots dating back to their university days, came together to form Moray Medical. Each pioneered surgical robotics: Mark Barrish functioned as a lead in intellectual property, and Phillip Laby, the scientist, developed core technologies that are commonplace in today’s surgical robotics. Moray Medical consists of dedicated and multi-talented personnel, advisers and investors with a deep understanding of transcatheter valve repair and other therapies, all supporting and developing Moray’s lifesaving technology.
Moray Featured on MedTech Chat
October 19, 2020 – Co-founder Mark Barrish appeared on MedTech Chat with Tom Donnelly, to discuss how Moray Medical is bringing the benefits of robotics to structural heart repair. (Linked page includes both podcast audio and written transcript.)
Moray Named One of “6 Best” Structural Heart Innovators
May 5, 2020 – CM Medical included Moray Medical’s technology in their “6 of the Best in Structural Heart” roundup. “They’ve made a robot which has less than 200 mechanical parts end to end, which is extremely unusual for the robotic medical device market.” Author James Christopher points out. “With leaders boasting companies like Intuitive and Accuray on their resumes, they also have the pedigree to back up the potential. So far Moray have managed to grow organically with their exceptional industry connections working in tandem with the innovative solution the product provides.”
Moray Medical Featured in Medgadget Newsletter
October 28, 2020 – Mark Barrish, CEO of Moray Medical, gave an interview to Medgadget, a well-known source for international medical technology news, health care trends, and medical research. Reporter Conn Hastings elicited clear, precise answers to questions ranging from the basics of heart valve failure to the advantages of augmented reality in Moray’s surgical technology.
Moray is one of 5 finalists in $500K MedTech Competition
September 25, 2020 – Moray Medical was selected as one of five finalists, from over 1,000 applicants, in the eighth annual industry accelerator competition managed by MedTech Innovator, the largest accelerator of medical devices in the world.
Virtual attendees of The MedTech Conference, the largest gathering of medtech industry leaders in North America, powered by AdvaMed, will vote online to choose the Grand Prize winner on Tuesday, October 6. The Grand Prize winner will take home a $350,000 non-dilutive cash prize and the title of MedTech Innovator 2020. The remaining four finalists will each receive a $25,000 cash prize, and several incubator space awards will be presented from JLABS. In total, $500,000 in prizes will be awarded.
MedTech Innovator received more than 1,000 applications from startups in 45 countries and 48 U.S. states for inclusion in its 2020 program. The five finalist companies are developing medical technology innovations in cardiology, pulmonology, mental health, and neurology. Read more here.